Sign In
Buy ABT
$90.51
-0.0200 (-0.0221%)
At Close: Jun 24, 2026
Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range
07:30am, Wednesday, 16'th Oct 2024
Sales of $10.6 billion driven by strong underlying base business performance Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digi
Abbott Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
03:53am, Wednesday, 16'th Oct 2024
Abbott Laboratories ABT will release earnings results for its third quarter, before the opening bell on Wednesday, Oct. 16.
3 Top-Rated Stocks to Watch as Earnings Approach: ABT, EFX, SLG
05:00pm, Tuesday, 15'th Oct 2024
Sporting a Zacks Rank #2 (Buy), here are three top-rated stocks that investors will want to consider as their Q3 results approach on Wednesday, October 16.
3 Stocks the Best Value Managers Are Buying
11:40am, Tuesday, 15'th Oct 2024
#Morningstar #ValueStocks #StockInvesting As value stocks rebound, here's where the smart money is investing. 00:00 Introduction 00:40 CVS CVS 01:39 Abbott ABT 02:26 Equifax EFX Susan Dziubsinki: I
Is a Surprise Coming for Abbott (ABT) This Earnings Season?
09:51am, Tuesday, 15'th Oct 2024
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus
10:34am, Monday, 14'th Oct 2024
ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
10:07am, Monday, 14'th Oct 2024
Abbott Laboratories will announce its Q3 results on the morning of 16th October, with earnings and topline growth largely expected to be in line with the Q2 trend. A year ago, all of Abbott's division
Diabetes Products To Drive Abbott's Q3
07:00am, Monday, 14'th Oct 2024
Abbott (NYSE: ABT) will report its Q3 2024 results on Wednesday, Oct 16. We expect the company to post revenue of $10.6 billion and earnings of $1.20 on a per share and adjusted basis, aligning with t
Abbott (ABT) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
10:20am, Friday, 11'th Oct 2024
Evaluate the expected performance of Abbott (ABT) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics
Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping
09:00am, Thursday, 10'th Oct 2024
Enrollment completed ahead of schedule in the global IDE for Abbott's Volt™ PFA System Global FOCALFLEX trial now underway for Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ Advisor�
Abbott (ABT) Earnings Expected to Grow: Should You Buy?
11:03am, Wednesday, 09'th Oct 2024
Abbott (ABT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
10:03am, Wednesday, 09'th Oct 2024
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
RBC Capital Raises Target Price for Abbott to $130
04:51am, Wednesday, 09'th Oct 2024
RBC Capital has recently adjusted its outlook on Abbott Laboratories (ABT, Financial), increasing its target price from $125 to $130. The firm continues to maintain an "Outperform" rating for the comp
Why Abbott (ABT) Outpaced the Stock Market Today
07:06pm, Tuesday, 08'th Oct 2024
Abbott (ABT) closed at $114.63 in the latest trading session, marking a +1.12% move from the prior day.
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
11:59am, Tuesday, 08'th Oct 2024
Abbott Laboratories's ABT MedTech portfolio is growing at a CAGR (compounded annual growing rate) of 11%-13%.
